Yes, pseudomyxoma peritonei (PMP) is considered a type of cancer. It is a rare cancer that usually starts in the appendix and can spread to the peritoneum, which is the lining of the abdominal cavity. The cancer cells in PMP produce a jelly-like substance called mucin, which can fill the abdominal cavity and cause a range of symptoms. While PMP is considered a type of cancer, it is often treated differently from other types of cancer due to its unique characteristics and behaviour.
It’s worth noting that PMP is usually classified as a low-grade malignancy, meaning that it is considered a form of cancer but is often slow-growing and not as aggressive as other types of cancer.
References
Appendiceal tumours and Pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment
Govaerts K, Lurvink RJ, De Hingh IHJT, et al (2021). Appendiceal tumours and Pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. European Journal of Surgical Oncology. 2021;47(1):11-35. Retrieved on April5, 2023, from doi:10.1016/j.ejso.2020.02.012
Pseudomyxoma peritonei: natural history and treatment
Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511-519. Retrieved on April 5, 2023, from doi:10.1080/02656736.2017.1310938
Pseudomyxoma Peritonei: Pathology, a Historical Overview, and Proposal for Unified Nomenclature and Updated Grading
Bradley, Robert F. MD; Carr, Norman J. FRCPath (2019). Pseudomyxoma Peritonei: Pathology, a Historical Overview, and Proposal for Unified Nomenclature and Updated Grading. AJSP: Reviews & Reports 24(3):p 88-93, 5/6 2019. Retrieved on April 5, 2023, from doi:10.1097/PCR.0000000000000305
In case you missed it
The Biology of pseudomyxoma peritonei (PMP)
Pseudomyxoma Survivor is supporting exciting new research into the biology of pseudomyxoma peritonei.
BromAc trial in Spain
Dr Arona Sanchez from Cordoba tells us about an exciting new trial for patients experiencing a recurrence of PMP.
Photo credit: Hellerhoff, CC BY-SA 3.0, via Wikimedia Commons
ERNs: Lend your support to the UK’s continued involvement
The voice of rare disease patients in Europe, EURORDIS, is supporting the Genetic Alliance UK’s #ProtectERNs campaign that calls on the UK government and the EU to secure the sustained involvement of the UK in European Reference Networks (ERNs) post Brexit. How can you help?